Loading clinical trials...
Loading clinical trials...
An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143 in Participants With Severe Hepatic Impairment and in Matched Healthy Adults
Conditions
Interventions
aumolertinib
Locations
3
United States
American Institute Research
Los Angeles, California, United States
Global Clinical Professionals
St. Petersburg, Florida, United States
Texas Liver Institute
San Antonio, Texas, United States
Start Date
March 30, 2022
Primary Completion Date
April 1, 2023
Completion Date
April 1, 2023
Last Updated
April 19, 2023
Lead Sponsor
EQRx International, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions